Exposure–response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer
van Nuland, M., Groenland, S. L., Bergman, A. M., Steeghs, N., Rosing, H., Venekamp, N., Huitema, A. D. R., Beijnen, J. H.
Published in Prostate cancer and prostatic diseases (01.06.2020)
Published in Prostate cancer and prostatic diseases (01.06.2020)
Get full text
Journal Article
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.
Published in Annals of oncology (01.10.2022)
Published in Annals of oncology (01.10.2022)
Get full text
Journal Article
Incidence of clinically significant toxicities in patients with high endoxifen concentrations
Groenland, S.L., Sanchez-Spitman, A.B., Moes, D.J.A.R., Koolen, S.L., Dezentjé, V.O., van Erp, N., Mathijssen, R.H.J., Guchelaar, H.-J., Huitema, A.D.R., Steeghs, N.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1486PDExposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
Groenland, S L, Geel, D R, Janssen, J M, Beijnen, J H, Burgers, S A, Smit, E F, Huitema, A D R, Steeghs, N
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
258PIncidence of clinically significant toxicities in patients with high endoxifen concentrations
Groenland, S L, Sanchez-Spitman, A B, Moes, D J A R, Koolen, S L, Dezentjé, V O, van Erp, N, Mathijssen, R H J, Guchelaar, H-J, Huitema, A D R, Steeghs, N
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
442OTherapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study
Groenland, S L, Van Eerden, R A G, Koolen, S L, Moes, D J A R, Desar, I M E, Touw, D J, Imholz, A L T, Reyners, A K L, Gelderblom, H, van Erp, N P, Mathijssen, R H J, Huitema, A D R, Steeghs, N
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1119PDInducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
Rischin, D, Groenland, S L, Lim, A M L, Martin-Liberal, J, Moreno, V, Trigo Perez, J M, Le Tourneau, C, Mathew, M, Cho, D C, Hansen, A R, Vincente-Baz, D, Maio, M, Italiano, A, Bauman, J R, Chisamore, M, Zhou, H, Ellis, C, Ballas, M, Hoos, A, Angevin, E
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1971PPharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Maio, M, Groenland, S L, Bauer, T, Rischin, D, Gardeazabal, I, Moreno, V, Trigo Perez, J M, Chisamore, M, Sadik Shaik, J, Rigat, F, Ellis, C, Chen, H, Gagnon, R, Scherer, S, Turner, D, Yadavilli, S, Ballas, M, Hoos, A, Angevin, E
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article